Categories: News

Beko Europe Appoints Akn Garzanl as New CEO


Akın Garzanlı, who previously served as CMO of Beko has been appointed as the CEO of Beko Europe

- Advertisement -

ISTANBUL, Oct. 1, 2025 /PRNewswire/ — Beko, a global leader in home appliances, today announced a new senior level appointment. Akın Garzanlı, who has been serving as Chief Marketing Officer of Beko since 2022 has been appointed as Beko Europe’s CEO and Beko’s Chief Commercial Officer in the Europe Region. He is taking over this role from Ragıp Balcıoğlu, who has been appointed as Beko’s Chief Marketing and Strategy Officer.

- Advertisement -

Akın Garzanlı has joined Beko for over 20 years ago. In his last role, leading 22 global and local brands in more than 55 countries with a marketing team spread across a large geography and developing marketing strategies that make a difference, he had been in charge of global brand management and marketing communications, industrial design, product management, small domestic appliances, content excellence, marketing insight and analytics, and marketing growth and transformation. In addition to the marketing function, he also oversaw the Middle East, Africa, and CIS regions as of 2023.

- Advertisement -

Garzanlı started his career in 2002, when he became responsible for Beko’s global markets. He has held key positions in the company’s global functions, including sales, product management, marketing and customer service. In 2018, he was appointed as Global Customer Care Director, and as of 2020, he assumed the role of Global Brand Director in addition to this position.

- Advertisement -

Garzanlı graduated from St. George’s Austrian High School in Istanbul and holds a bachelor’s degree from Istanbul University in the field of Management. He earned his MBA from the Koç University. Garzanlı also completed several programs at Harvard Business School and Kellogg School of Management.

- Advertisement -

Akın Garzanlı has brought energy and clarity to Beko’s global marketing capability, and he knows how to turn consumer insight into performance. Beko Europe has a wide brand portfolio, and Garzanlı’s experience managing and growing multiple brands across markets, combined with his agile approach, will help Beko get closer to its customers and turn brand strength into further results.

- Advertisement -

Photo: https://mma.prnewswire.com/media/2786746/Beko_Europe_CEO.jpg
Logo: https://mma.prnewswire.com/media/2765641/5535155/Beko_Logo_Corporate.jpg

- Advertisement -

 

- Advertisement -

 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/beko-europe-appoints-akn-garzanl-as-new-ceo-302572113.html

- Advertisement -

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

8 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

8 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

8 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

8 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

8 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

8 hours ago